Receiving a Second Opinion

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and patient well-being.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Dr. Rita Mukhtar sits down for a conversation with Dr. Joshua Sabari to discuss the potential use of ctDNA to guide breast cancer therapy.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic pancreatic ductal adenocarcinoma.

After my breast cancer diagnosis, faith guided me through fear, and in passing on a blessed bracelet, I found healing and an unexpected reconnection.